Established therapies are targeted on the epidermal growth factor receptor (EGFR), such as Panitumumab [1–4] and Cetuximab [5–8] (two monoclonal antibodies) treatment for metastatic colorectal carcinoma, Gefitinib for NSCLC, or Erlotinib for NSCLC and for pancreatic carcinoma. Here, EGFR is linked to non-small cell lung carcinoma.